Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 3

Change in monthly headache days during 12 weeks A) overall and B) by migraine classification. LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in the monthly average number of headache days of at least moderate severity during 12 weeks of double-blind treatment. Part A includes data for participants ≥60 years and the overall pooled population; part B includes data for participants ≥60 years by migraine diagnosis (chronic or episodic migraine). aP < 0.05 vs placebo. bP < 0.005 vs placebo. cP < 0.0001 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us